Tuberculosis

Statistical model useful for determining prevalence of TB in people with BCG vaccination

Published in Vaccine Weekly, June 26th, 2002

by Maria G. Essig, MS, ELS, senior medical writer - No significant difference existed between the prevalence of tuberculosis (TB) infection in people with a Bacillus Calmette-Guerin (BCG) scar and those without such a scar, say researchers in Switzerland.

BCG is used as a vaccine to prevent tuberculosis where the disease is widespread. However, the vaccine can stimulate the production of antibodies that cause a positive TB skin test, making it difficult to determine whether or not a person is infected with TB.

To determine the prevalence of TB in people both with and without BCG vaccination, B.E. Neuenschwander and colleagues at the Federal Office...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Vaccine Weekly

Source: Vaccine Weekly (2002-06-26)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry